GlassScriptPhysician profile
Hanna A Lin
NPI 1831100866
$3,056.01
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,750 · 2020: $634 · 2021: $280 · 2022: $119 · 2023: $141 · 2024: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $273.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $454.58 | 2019-2022 | |
| Amgen INC. | $358.60 | 2019-2024 | Evenity |
| Astrazeneca Pharmaceuticals LP | $259.70 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $189.28 | 2019-2020 | |
| Glaxosmithkline, LLC. | $144.90 | 2019-2020 | |
| Astellas Pharma US INC | $143.78 | 2019-2020 | |
| Portola Pharmaceuticals, LLC | $137.61 | 2020 | |
| Merck Sharp & Dohme LLC | $135.48 | 2019-2020 | |
| Harmony Biosciences LLC | $127.41 | 2020-2021 | |
| Eisai INC. | $125.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $123.86 | 2021 | |
| Radius Health, INC. | $109.88 | 2019-2020 | |
| Averitas Pharma INC. | $98.90 | 2023 | Qutenza |
| Novartis Pharmaceuticals Corporation | $84.51 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.53 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $68.33 | 2019-2021 | |
| Pfizer INC. | $65.85 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $48.96 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.61 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $28.11 | 2019 | |
| Allergan, INC. | $26.03 | 2019 | |
| Supernus Pharmaceuticals, INC. | $23.34 | 2019 | |
| Esperion Therapeutics, INC. | $22.97 | 2021 | |
| Edwards Lifesciences Corporation | $21.95 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Jazz Pharmaceuticals INC. | $20.92 | 2019 | |
| Daiichi Sankyo INC. | $20.24 | 2021 | |
| Lilly USA, LLC | $20.19 | 2023 | Mounjaro |
| Kvk-Tech, INC. | $16.95 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $16.95 | 2019 | |
| Ucb, INC. | $14.87 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.77 | 2019 | |
| Sanofi Pasteur INC. | $12.70 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hanna Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.